Trial Profile
A PhaseII, Open-Label, Multinational, Multi-Centre, Sequential Group, Dose-Escalation Study to Assess the Safety and Antiviral Activity of LB80380 for 12 Weeks in Patients With Lamivudine-Refractory Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Besifovir (Primary) ; Adefovir dipivoxil; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors LG Life Sciences
- 14 May 2009 New trial record